Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34)
-
Published:2020-06
Issue:
Volume:132
Page:43-52
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
Singer Christian F., Pfeiler Georg, Hubalek Michael, Bartsch Rupert, Stöger Herbert, Pichler Angelika, Petru Edgar, Bjelic-Radisic Vesna, Greil Richard, Rudas MargarethaORCID, Maria Tea Muy-Kheng, Wette Viktor, Petzer Andreas L., Sevelda Paul, Egle Daniel, Dubsky Peter C., Filipits MartinORCID, Fitzal Florian, Exner Ruth, Jakesz Raimund, Balic MarijaORCID, Tinchon Christoph, Bago-Horvath Zsuzsanna, Frantal Sophie, Gnant MichaelORCID
Funder
Roche Novartis Amgen Astra Zeneca Pfizer Celgene Merck AstraZeneca Bayer Boehringer Ingelheim Lilly Myriad Genetics Inc. GlaxoSmithKline Accelsiors OBI-Pharma Merck KGaA
Subject
Cancer Research,Oncology
Reference19 articles.
1. Technology evaluation: BLP-25, biomira Inc;Morse;Curr Opin Mol Therapeut,2001 2. A MUC1-targeted peptide vaccine therapy in prostate cancer;R1;Expet Opin Biol Ther,2007 3. A peptide vaccine strategy in non small cell lung cancer;R1;Clin Cancer Res,2007 4. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer;Rakha;Mod Pathol,2005 5. MUC1: a multifunctional cell surface component of reproductive tissue epithelia;Brayman;Reprod Biol Endocrinol,2004
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|